Development of Gene Chip Technology for Vascular Risk Assessment
Screening for differential expression of vascular risk-related molecules
Full description
Prevention of cardiovascular disorders such as myocardial
infarction and stroke is an area of major public health
importance. Currently, several risk factors for future
cardiovascular disorders have been described and are in wide
clinical use in the detection of individuals at high risk.
However a large number of cardiovascular disorders occur in
individuals with apparently low to moderate risk profiles,
thereby limiting the ability to identify such patients.
Moreover, may of the risk factors require accurate gathering
of clinical information. An objective panel of biological
markers which allow one to predict an individual's risk of
vascular disease is therefore needed.
The present provisional patent application is directed to
utilizing blood mononuclear cells to evaluate vascular disease
risk and determine a preventive regimen for reduction or
minimization of such risk. The method includes screening for
differential expression of vascular risk-related molecules,
such as DNA binding/transcription factor proteins, lysosomal
or protein degradation enzymes, adhesion molecules,
metabolism molecules, intracellular signaling molecules,
immune response molecules and apoptosis. The technology
is available to a collaborator for monitoring stroke treatment
protocols, for definition of clinical trial protocol candidates, or
for developing an "assessment chip" that could be used to
predict an individual's risk of developing a stroke in the future.
Patent information
U.S. Provisional Application No. 60/687,515 filed 03 Jun 2005
(HHS Reference No. E-030-2005/0-US-01); U.S. Provisional
Application No. 60/691,730 filed 17 Jun 2005 (HHS Reference
No. E-030-2005/1-US-01); PCT Application No.
PCT/US2006/021491 filed 02 Jun 2006 (HHS Reference No. E-
030-2005/0-PCT-02)
Inventors: Alison E. Baird (NINDS) et al.
Type of business relationship sought
Licensees sought.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with
the inventors: The NINDS Stroke Neuroscience Unit is
seeking statements of capability or interest from parties
interested in collaborative research to further develop,
evaluate, or commercialize a vascular risk genetic chip
technology. We seek a collaborative partner in the
development of a chip that could be used to predict an
individual's risk of developing a stroke in the future and to
monitor the effectiveness of preventive measures once they
have been instituted. Please contact Heather Gunas at
gunash@mail.nih.gov for more information.